Bobbie-Jo Webb-Robertson

Director

Pacific Northwest National Laboratory
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (21)

Extracellular vesicles (EVs) are membrane‐bound particles secreted by cells, playing crucial roles in intercellular communication. The composition of EVs can undergo changes in response to stress and disease conditions, making them excellent biomarker candidates. However, extracting protein information from EVs can be challenging due to their low abundance in complex biofluids and copurification with contaminant proteins and particles. Techniques to enrich EVs have their strengths and limitations, without one being able to purify EVs to complete homogeneity. This can lead to compromised recovery rates and increased complexity, making data interpretation difficult. In this viewpoint article, we explore the concept that better characterization of EV composition, followed by quantification of EV proteins in complex samples, might be a more viable route for biomarker development. Mass spectrometers can provide reproducible deep coverage of the EV proteome, despite sample impurities. This paradigm shift presents opportunities to integrate advanced bioinformatics tools to refine the EV proteome landscape, identify novel biomarkers, and streamline validation processes in biomarker development. By focusing on leveraging technology rather than achieving absolute purity, this approach can transform current practices and open opportunities for robust biomarker discovery. Herein, we highlight not only such opportunities but also challenges to implement this concept. Summary Extracellular vesicles (EVs) have enormous potential as biomarkers of diseases, as they can carry signatures of the cells they are derived from and the pathogenesis process. Biofluids, such as blood plasma, are highly complex and contain many components with physicochemical properties similar to those of EVs, making it challenging to obtain pure EV fractions. Challenges in obtaining pure preparations represent a main hurdle for studying EVs, and their components are potential biomarkers. This article explores the concept of studying EV proteins within complex samples, discussing opportunities and needs to move this field forward.

Year:

2026

Year:

2026

Year:

2026

Plasma extracellular vesicles (EVs) are considered excellent sources for biomarker discovery since they carry signatures of their cellular origin and disease processes. In this paper, we evaluate the potential of plasma EV proteomics analysis for identifying predictive biomarkers of developing type 1 diabetes (T1D), which results from autoimmune destruction of insulin-producing β cells in the islet. We used strong anion exchange beads (Mag-Net) to capture plasma EVs from 19 donors with islet autoimmunity (diagnosed by circulating autoantibodies against islet proteins – AAB+) vs. 17 control individuals and analyzed their protein cargo by mass spectrometry. The analysis identified and quantified 5,480 proteins, a 3.2-fold increase in proteome coverage compared to our previous T1D biomarker proteomics study that used whole plasma depleted of the 14 most abundant proteins. The Mag-Net approach also detected 1,306 out of the 1,717 proteins (76%) that we previously verified as EV proteins. Statistical tests revealed 448 proteins to be differentially abundant in AAB+ vs control volunteers, including 69 previously verified EV proteins. A functional-enrichment analysis resulted in overrepresentation of 25 pathways among the differentially abundant proteins, including pathways related to autoimmune response and lipid metabolism. The capacity of this data to predict AAB+ was tested with a machine learning analysis using a random forest model, resulting in a receiver operating characteristic-area under the curve of 0.81. Overall, our study indicates that plasma EV proteomics analysis can be an exciting approach for studying biomarkers for developing T1D. Significance of the study Type 1 diabetes (T1D) is a disease characterized by the body’s inability to produce insulin and consequently, to control blood glucose levels. Despite the initial trigger being unclear, the disease development process involves an autoimmune response to the islets of Langerhans, resulting in the death of insulin-producing β cells. There is no cure for the disease, and treatment relies on exogenous administration of insulin. Therefore, preventive therapies that block the autoimmune process are attractive for treating T1D. In fact, anti-CD3 antibody (Teplizumab) delays the onset of T1D by 2 years by targeting T cells. Predictive biomarkers for developing T1D are needed to aid the development and implementation of new therapies and to identify the initial trigger and mechanisms of the islet autoimmune process. In this paper, we assess the potential of plasma extracellular vesicle (EV) proteomics analysis for identifying predictive biomarkers of T1D. Our results show excellent potential of the approach, opening opportunities to perform broader studies to identify biomarkers for developing T1D.

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Context Alterations in RNA splicing may influence protein isoform diversity that contributes to or reflects the pathophysiology of certain diseases. Whereas specific RNA splicing events in pancreatic islets have been investigated in models of inflammation in vitro, how RNA splicing in the circulation correlates with or is reflective of type 1 diabetes (T1D) disease pathophysiology in humans remains unexplored. Objective To use machine learning to investigate if alternative RNA splicing events differ between individuals with and without new-onset T1D and to determine if these splicing events provide insight into T1D pathophysiology. Methods RNA deep sequencing was performed on whole blood samples from 2 independent cohorts: a training cohort consisting of 12 individuals with new-onset T1D and 12 age- and sex-matched nondiabetic controls and a validation cohort of the same size and demographics. Machine learning analysis was used to identify specific isoforms that could distinguish individuals with T1D from controls. Results Distinct patterns of RNA splicing differentiated participants with T1D from unaffected controls. Notably, certain splicing events, particularly involving retained introns, showed significant association with T1D. Machine learning analysis using these splicing events as features from the training cohort demonstrated high accuracy in distinguishing between T1D subjects and controls in the validation cohort. Gene Ontology pathway enrichment analysis of the retained intron category showed evidence for a systemic viral response in T1D subjects. Conclusion Alternative RNA splicing events in whole blood are significantly enriched in individuals with new-onset T1D and can effectively distinguish these individuals from unaffected controls. Our findings also suggest that RNA splicing profiles offer the potential to provide insights into disease pathogenesis.

Year:

2024

Human infections caused by viral pathogens trigger a complex gamut of host responses that limit disease, resolve infection, generate immunity, and contribute to severe disease or death. Here, we present experimental methods and multi-omics data capture approaches representing the global host response to infection generated from 45 individual experiments involving human viruses from the Orthomyxoviridae , Filoviridae , Flaviviridae , and Coronaviridae families. Analogous experimental designs were implemented across human or mouse host model systems, longitudinal samples were collected over defined time courses, and global multi-omics data (transcriptomics, proteomics, metabolomics, and lipidomics) were acquired by microarray, RNA sequencing, or mass spectrometry analyses. For comparison, we have included transcriptomics datasets from cells treated with type I and type II human interferon. Raw multi-omics data and metadata were deposited in public repositories, and we provide a central location linking the raw data with experimental metadata and ready-to-use, quality-controlled, statistically processed multi-omics datasets not previously available in any public repository. This compendium of infection-induced host response data for reuse will be useful for those endeavouring to understand viral disease pathophysiology and network biology.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (20)

Xueyun Zheng

Scientist

Pacific Northwest National Laboratory

UNITED STATES
View details

Carmella Evans-Molina

Eli Lilly and Company Professor of Pediatric Diabetes

Indiana University School of Medicine

UNITED STATES
View details

Xiaowei Hu

Research Assistant Professor

University of Virginia

UNITED STATES
View details

David Degnan

Assistant Teaching Professor

University of Oregon

UNITED STATES
View details

Heather Gustafson

Assistant Professor

University of Washington

UNITED STATES
View details

Stephen Rich

Harrison Professor and Founding Director (Emeritus)

University of Virginia

UNITED STATES
View details

Michael Muniak

Assistant Staff Scientist

Oregon Health & Science University

UNITED STATES
View details

Lee Ann McCue

Senior Research Scientist

Pacific Northwest National Laboratory

UNITED STATES
View details

Wei-Jun Qian

Staff Scientist

Pacific Northwest National Laboratory

UNITED STATES
View details

Javier Flores

Research Assistant Professor

The University of Iowa

UNITED STATES
View details

Corinne Summers

Seattle Children's Research Institute

UNITED STATES
View details

Deepti Tanjore

Head of Department, PEA and Director of ABPDU

Lawrence Berkeley National Laboratory

UNITED STATES
View details

Raghavendra Mirmira

Professor

University of Chicago

UNITED STATES
View details

Young-Mo Kim

Senior Scientist

Pacific Northwest National Laboratory

UNITED STATES
View details

Chaitra Rao

Indiana University School of Medicine

UNITED STATES
View details

Ernesto Nakayasu

Scientist

Pacific Northwest National Laboratory

UNITED STATES
View details

Marian J Rewers

professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Katrina Waters

Chief Scientist

Pacific Northwest National Laboratory

UNITED STATES
View details

Emily K Sims

Indiana University School of Medicine

UNITED STATES
View details

Tom Metz

Staff Scientist / Metabolomics Team Lead

Pacific Northwest National Laboratory

UNITED STATES
View details